Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

Moneyplus
If you want China have LDC at lest your bets will be spread. They hold stakes in the company AND get paid as company advisers and fund managers. Three legs to the stool

Mark
Thanks for your visit, as you say the revenue from the sale of the strips is potentially massive as the strips are throw away can only be used once and must be used with each monitor. Yes 6p for MDY shares are starting to look very cheap.

I think 6p seems too cheap and I'm still thanking you for showing me this one driver. marksp-thanks for telling me about LDC-I'm almost embarrassed to tell you I'm in those too as driver is beginning to think I'm a china junkie!!

Nice bounce today 8.57% up 8p to 9p next step up IMO.

On it's way to that next leg up 9p 17.11% up today.

D Wong ....to take up top-job at Galleon [GON] - presumably to-do to their sp what he's done to MDY.
Pitty MDY did not think this needed an RNS - if he goes, the sp will only get better.

Cheers hangon
Looks like a new ceo or a take over either one would lift the sp, looking good.

Galleon Holdings plc
('Galleon' or the 'Company')

Appointment of Director


Galleon Holdings plc, the intellectual property owner and developer in the
children's entertainment sector, is pleased to announce the appointment of David
Wong as Executive Chairman, with immediate effect.

David Wong is an entrepreneur and private equity specialist who has experience
and a successful track record in growing businesses in both the medical and
multi media sectors. Currently he is Chairman of AIM listed medical products
group, Medisys PLC. Recently, through investment fund, Imagination Holdings
Limited, he has been investing successfully in the children's entertainment
sector and has built a wide portfolio of investments in the multi media area.

March 28, 2006 - Hypoguard Receives 510(k) Clearance to Market Assure Pro Blood Glucose Monitoring System.

http://www.hypoguard.com/press_release_detail_oid_108592.html

Alpesh Patel A weekly look at market opportunities and pitfalls

Alpesh B. Patel is one of the UK's best-known traders and financial journalists. He writes a regular column for the Financial Times, has written seven bestselling books on trading, and makes regular television appearances for Bloomberg, Sky Television, Channel 4, The Money Channel, and the BBC.

Crazy Small Stock
These are high risk volatile stocks which could move sharply higher or move sharply lower in my view, but will almost certainly not stand still. Names on the radar include: Medisys, Aukett Fitzroy, Network Technology.

http://www.advfn.com/column6/equities-booming-rally.html

My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

Driver - surely this has been overdone - I have just bought on a speculative buy at 3.23

Baza

baza
I dont think so baz the way it looks after paying back the term note loan facility of $9.75 million (approximately 5.5 million) and overdraft facility of $4.25m (approximately 2.4 million) with Bank of Scotland pl You are left with a shell company at about 3p a share what a sham good luck.

MMmmmmmm - I think you are right - your maths are better than mine.

B

OUCH--some you win some you lose!!

moneyplus: Ouch is appropriate. Judging by the timing of this, it looks clear that Medisys will become a "clean" shell with adequate funds to be invested wisely. I would not be surprised if after the shareholders give approval for the "sell off", a secondary offering will be planned. With a clean cash shell, it will not be long before predators circle. This could prove to be a longer term winner.

A good post from another board on todays sell out.

Once again the shareholders are being shafted as the Executive Chairman Dr.Wong appears to treat the company as though its his own.

So some points about todays announcement

1. Once again this Company has been devalued by an announcement from the management.
2. The management seek to transfer the shares to AIM, therefore shares held in ISAs will have to be sold, causing a further reduction in the price, possible enabling the management to buy up and take control of the company at a value far below even the current 3p.
3. By the looks of it, the deals and price of the sales have been agreed.
4. What ever happened to the Roche settlement.
5. This going to become an investment company, with one employee, who could be both judge and jury, that person beingDr.Wong?
6. Menarini whats happening ?
7. Announcement about a "considerable improvement" in trading during the first four months of its financial year , only 2 month ago. Was this designed to mislead?

So how do we get rid of the directors,

I want to see these guys off the board before any sale of the company, so the likes of Wong will only benefit from the remaining value of the 20m shares in his Trust.

S/HOLDERS SHAFTED again -for 42m dollars,long before egm on 4/05/06,whats left for us,surely not atop/up opportunity,why not whole co.,does this make any sence for s/holders,any views.

This article just about sums it up.The site is free to register.

http://www.proactiveinvestors.com/registered/articles/article.asp?MDY2

Unbelievable. That about sums up Medisys Plc (MDY) in my mind. Over the years MDY has lurched from one would be company making line of medical products after another.

Today, MDY finally threw in the towel and admitted it was finding life hard going in the ultra competitive markets of blood glucose monitoring (BGM) products. Along the way Medisys has burned through an impressive amount of shareholder money and bank debt on research & development, acquisitions, disposals and write-offs.

Mr Wong has had a few bad years it's true; but we learn that he's happier doing deals with small pharmas - the Q, is will NDY have any cash left after they have paid the Bank and fat bonuses to failing staff?
/
With the prospect about evens - (since many small pharmas are finding cash difficult to find), there is a slim chance Wong could be Right for Wunce.
Who knows?
Frankly with the sp looking this low it's hardly worth much to sell them.

this share pongs! .... if you have them, either hold though goodness knows what for, except perhaps to crystalise a loss at the end of the tax year ..... if you don't hold them, then AVOID